FOSTER CITY, CA -- (Marketwired) -- 05/28/13 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.

A study of analyst recommendations at the major brokerages shows that SciClone Pharmaceuticals, Inc. (NASD: SCLN) is the #61 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity.

New York, NY - (NISMAGAZINE) - 05/28/2013- SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) closed at $4.86 after falling 2.21% which is a fall of $0.11 as compared to its previous close of $4.97.

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) announced that it entered into a drug contract with Zensun (Shanghai) Science & Technology Co.

SciClone Pharmaceuticals Inc. (SCLN) said it entered into a drug agreement with Zensun (Shanghai) Science & Technology Co.

Big pharma drug delivery partnering company profiles Abbott Actavis Inc (formerly Watson Pharmaceuticals) Actavis (merged with Watson Pharmaceuticals Oct 2012) Actelion Allergan Amgen Astellas AstraZeneca Baxter International Bayer Biogen Idec ...

3SBio Inc. (NSDQ: SSRX) will go private (see story). A full 87% of company's shareholders voted in favor of the ... Company News. Janssen Pharmaceutical Companies, a division of Johnson & Johnson (NYSE: JNJ), announced it has four new medical entities ...